Reclassification of the Candida haemulonii Complex as Candida haemulonii (C. haemulonii Group I), C. duobushaemulonii sp. nov. (C. haemulonii Group II), and C. haemulonii var. vulnera var. nov.: Three Multiresistant Human Pathogenic Yeasts

被引:186
作者
Cendejas-Bueno, E. [2 ]
Kolecka, A. [1 ]
Alastruey-Izquierdo, A. [2 ]
Theelen, B. [1 ]
Groenewald, M. [1 ]
Kostrzewa, M. [3 ]
Cuenca-Estrella, M. [2 ]
Gomez-Lopez, A. [2 ]
Boekhout, T. [1 ,4 ]
机构
[1] CBS KNAW Fungal Biodivers Ctr, Utrecht, Netherlands
[2] Inst Salud Carlos III, Serv Micol, Ctr Nacl Microbiol, Majadahonda, Madrid, Spain
[3] Bruker Daltonik GmbH, Bioanalyt Dev, Bremen, Germany
[4] Univ Med Ctr, Dept Internal Med & Infect Dis, Utrecht, Netherlands
关键词
SUSCEPTIBILITY TESTING AFST; AMPHOTERICIN-B-RESISTANT; ANTIFUNGAL SUSCEPTIBILITY; EUROPEAN COMMITTEE; CLINICAL-FEATURES; BIOFILM FORMATION; ALBICANS; IDENTIFICATION; DUBLINIENSIS; FUNGEMIA;
D O I
10.1128/JCM.02248-12
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The Candida haemulonii species complex is currently known as C. haemulonii groups I and II. Here we describe C. haemulonii group II as a new species, Candida duobushaemulonii sp. nov., and C. haemulonii var. vulnera as new a variety of C. haemulonii group I using phenotypic and molecular methods. These taxa and other relatives of C. haemulonii (i.e., Candida auris and Candida pseudohaemulonii) cannot be differentiated by the commercial methods now used for yeast identification. Four isolates (C. haemulonii var. vulnera) differed from the other isolates of C. haemulonii in the sequence of the internal transcribed spacer (ITS) regions of the nuclear rRNA gene operon. The new species and the new variety have a multiresistant antifungal profile, which includes high MICs of amphotericin B (geometric mean MIC, 1.18 mg/liter for C. haemulonii var. vulnera and 2 mg/liter for C. duobushaemulonii sp. nov) and cross-resistance to azole compounds. Identification of these species should be based on molecular methods, such as sequence analysis of ITS regions and matrix-assisted laser desorption ionization-time of flight mass spectrometry.
引用
收藏
页码:3641 / 3651
页数:11
相关论文
共 41 条
[1]   Phenotypic and molecular characterization of Candida nivarzensis sp nov., a possible new opportunistic fungus [J].
Alcoba-Flórez, J ;
Méndez-Alvarez, S ;
Cano, J ;
Guarro, J ;
Pérez-Roth, E ;
Arévalo, MD .
JOURNAL OF CLINICAL MICROBIOLOGY, 2005, 43 (08) :4107-4111
[2]   Rapid methods to extract DNA and RNA from Cryptococcus neoformans [J].
Bolano, Alessandro ;
Stinchi, Silvia ;
Preziosi, Roberta ;
Bistoni, Francesco ;
Allegrucci, Massimo ;
Baldelli, Franco ;
Martini, Alessandro ;
Cardinali, Gianluigi .
FEMS YEAST RESEARCH, 2001, 1 (03) :221-224
[3]   Use of amplified fragment length polymorphism analysis to identify medically important Candida spp., including C-dubliniensis [J].
Borst, A ;
Theelen, B ;
Reinders, E ;
Boekhout, T ;
Fluit, AC ;
Savelkoul, PHM .
JOURNAL OF CLINICAL MICROBIOLOGY, 2003, 41 (04) :1357-1362
[4]   Identification of Pathogenic Rare Yeast Species in Clinical Samples: Comparison between Phenotypical and Molecular Methods [J].
Cendejas-Bueno, Emilio ;
Gomez-Lopez, Alicia ;
Mellado, Emilia ;
Rodriguez-Tudela, Juan L. ;
Cuenca-Estrella, Manuel .
JOURNAL OF CLINICAL MICROBIOLOGY, 2010, 48 (05) :1895-1899
[5]   Candida bracarensis sp nov., a novel anamorphic yeast species phenotypically similar to Candida glabrata [J].
Correia, A ;
Sampaio, P ;
James, S ;
Pais, C .
INTERNATIONAL JOURNAL OF SYSTEMATIC AND EVOLUTIONARY MICROBIOLOGY, 2006, 56 :313-317
[6]   A case of Candida haemulonii osteitis: clinical features, biochemical characteristics, and antifungal resistance profile [J].
Crouzet, J. ;
Sotto, A. ;
Picard, E. ;
Lachaud, L. ;
Bourgeois, N. .
CLINICAL MICROBIOLOGY AND INFECTION, 2011, 17 (07) :1068-1070
[7]   Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi [J].
Cuenca-Estrella, M ;
Gomez-Lopez, A ;
Mellado, E ;
Buitrago, MJ ;
Monzon, A ;
Rodriguez-Tudela, JL .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (03) :917-921
[8]   In vitro susceptibilities of bloodstream isolates of Candida species to six antifungal agents:: results from a population-based active surveillance programme, Barcelona, Spain, 2002-2003 [J].
Cuenca-Estrella, M ;
Rodriguez, D ;
Almirante, B ;
Morgan, J ;
Planes, AM ;
Almela, M ;
Mensa, J ;
Sanchez, F ;
Ayats, J ;
Gimenez, M ;
Salvado, M ;
Warnock, DW ;
Pahissa, A ;
Rodriguez-Tudela, JL .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2005, 55 (02) :194-199
[9]   Multicenter evaluation of the reproducibility of the proposed antifungal susceptibility testing method for fermentative yeasts of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antimicrobial Susceptibility Testing (AFST-EUCAST) [J].
Cuenca-Estrella, M ;
Moore, CB ;
Barchiesi, F ;
Bille, J ;
Chryssanthou, E ;
Denning, DW ;
Donnelly, JP ;
Dromer, F ;
Dupont, B ;
Rex, JH ;
Richardson, MD ;
Sancak, B ;
Verweij, PE ;
Rodríguez-Tudela, JL .
CLINICAL MICROBIOLOGY AND INFECTION, 2003, 9 (06) :467-474
[10]   Update on the epidemiology and diagnosis of invasive fungal infection [J].
Cuenca-Estrella, Manuel ;
Bernal-Martinez, Leticia ;
Jose Buitrago, Maria ;
Victoria Castelli, Maria ;
Gomez-Lopez, Alicia ;
Zaragoza, Oscar ;
Rodriguez-Tudela, Juan Luis .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2008, 32 :S143-S147